A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Latest Information Update: 30 Aug 2024
At a glance
- Drugs ANX 005 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Proof of concept
- Sponsors Annexon
- 26 Mar 2024 According to an Annexon media release, company plans to submit the Phase 2a data for presentation at an upcoming medical conference later this year.
- 26 Mar 2024 Topline results from this trial presented in an Annexon media release.
- 26 Mar 2024 Status changed from recruiting to completed, according to an Annexon media release.